Search clinical trials for: Upadacitinib (ABT-494)

Total 1535 results

AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Hepatitis C Virus (HCV)
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

Ulcerative Colitis

United States, Austria, Belgium, Canada, Czech Republic, Germany, Hungary, Italy, Netherlands, Poland, Puerto Rico, Slovakia, Sweden
AbbVie

Completed

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland (REACH)

Chronic Hepatitis C
AbbVie
Cato Research; IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)

Chronic Hepatitis C
Abbott
Genentech, Inc.

Withdrawn

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

B-cell Chronic Lymphocytic Leukemia
Bristol-Myers Squibb

Terminated

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

HIV
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Arthritis | Psoriatic
Beni-Suef University

Completed

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Chronic Hepatitis C Virus Infection

Egypt
Abbott Medical Devices

Recruiting

JETi Hong Kong Post Market Study (PMS)

Peripheral Artery Thrombosis | Peripheral Venous Thrombosis

Hong Kong
Abbott Medical Devices

Recruiting

Amulet™ ADVANCE LAA

Stroke | Atrial Fibrillation | Bleeding

United States
Abbott Medical Devices

Completed

TactiFlex Paroxysmal Atrial Fibrillation IDE Trial

Paroxysmal Atrial Fibrillation

United States, Canada, Australia, Austria, Czechia, Germany, Hong Kong, Italy, Netherlands, Taiwan
Northwestern University
Abbott

Completed

Consumer Understanding and Use of Medication Guides

Revised Medication Guide Formats

United States
The Second People's Hospital of GuangDong Province

Completed

Angiography Combination Laparoscopy in Patients With Obscure Gastrointestinal Bleeding

Surgical Wound

China
Centre Francois Baclesse
GRECAN

Completed

Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors (ABT737 exvivo)

Ovarian Cancer

France
Beni-Suef University

Completed

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Hepatitis C Virus Infection
Tufts Medical Center

Completed

Mechanism of Action Study for Psoriasis (MOA)

Psoriasis

United States
AbbVie
Genentech, Inc.

Completed

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
GlycoMimetics Incorporated

Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Multiple Myeloma

Ireland, Denmark, United Kingdom, Germany
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Chronic Hepatitis C
AbbVie

Completed

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis
Abbott

Completed

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Rheumatoid Arthritis

United States, Canada, Puerto Rico, Australia, Germany, United Kingdom
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
AbbVie

Completed

Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

Asthma
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Chronic Hepatitis C | Hepatitis C Virus
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
AbbVie
Raffeiner GmbH

Completed

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (Adherence)

Rheumatoid Arthritis | Plaque Psoriasis | Ulcerative Colitis | Psoriatic Arthritis | Ankylosing Spondylitis | Crohn´s Disease
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

Crohn's Disease
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Intestinal Behçet's Disease

Japan
Abbott
Eisai Limited

Completed

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
AbbVie (prior sponsor, Abbott)
Prostate Cancer Clinical Trials Consortium

Completed

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Prostate Cancer
Abbott

Completed

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Shanghai Public Health Clinical Center

Completed

The Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects

Drug Interaction

China
AbbVie

Completed

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Glioblastoma Multiforme
AbbVie
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Solid Tumors | Lymphoid Malignancy
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie (prior sponsor, Abbott)

Completed

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Moderate to Severe Plaque Psoriasis

Russian Federation
Abbott

Completed

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Denmark, Germany, Netherlands
AbbVie
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer...

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia, Austria, Bulgaria, Germany, Italy, Spain, Israel, Brazil, Romania, United Kingdom
AbbVie

Active, not recruiting

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Chronic Lymphocytic Leukemia (CLL)

Austria, Germany, Switzerland
AbbVie

Completed

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

Rheumatoid Arthritis
University Hospital Tuebingen

Unknown

Early Antibiotic Therapy and Vaccination

Vaccination Reaction

Germany
AbbVie
Genentech, Inc.

Completed

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Solid Tumors
AbbVie
Genentech, Inc.

Completed

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Non-Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Completed

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Choroid Plexus Tumor | Childhood Craniopharyngioma | Childhood Ependymoblastoma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma and other conditions

United States
AbbVie
Genentech, Inc.

Withdrawn

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Non-Hodgkin's Lymphoma

United States

3

Subscribe